Faeth Therapeutics stock rating reiterated at Buy by H.C. Wainwright
H.C. Wainwright reiterated a Buy rating and $60 price target for Faeth Therapeutics (FTH) after positive Phase 2 trial results for PIKTOR. The trial showed a 33% objective response rate and 7.4-month median progression-free survival, outperforming typical chemotherapy benchmarks. Despite a 45% stock decline, analysts highlight the drug's potential and manageable toxicity. Other firms also reiterated positive ratings, and the company appointed a new board member.
How this was made
The 30-second read
Why it matters
The Phase 2 topline results exceed typical salvage‑chemotherapy benchmarks, prompting multiple analysts to reaffirm Buy ratings and raise price targets to $60.
Market read
The trial data provide fresh, material information for a micro‑cap biotech, likely driving short‑term price movement.
What to watch
Potential safety concerns or competitive pipeline developments could temper upside.
Background
Faeth Therapeutics (NASDAQ:FTH) is a small‑cap oncology biotech focusing on endometrial cancer therapies.
Ticker impact
Faeth Therapeutics announced preliminary Phase 2 results showing a 33% objective response rate and 7.4‑month median progression‑free survival, prompting analysts to reiterate Buy ratings and raise price targets.
likely upside as the market incorporates the encouraging efficacy data.
Analyst coverage upgrades and a $60 target suggest the market will bid the stock higher on the trial news.
Market effects
Strengthens the oncology biotech sector as a new therapy shows promise.
US biotech investors may see increased interest in similar Phase 2 programs.
Limited to biotech investors; no broad market effect.
Counterpoint
The data are preliminary; efficacy may not translate to later-stage trials, so the rally could be premature.
Key entities
- companyFaeth Therapeutics
Biotech developing PIKTOR for endometrial cancer.
- analystH.C. Wainwright
Equity research firm reiterating Buy rating.
